2 active not recruiting, 1 completed. 2 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow AZD9592: new trials by email Literature Review of AZD9592 trials Research Report on AZD9592
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC Rilvegostomig, Volrustomig, Sabestomig - Head and Neck Squamous Cell Carcinoma | Early Phase 1 | Completed | Presage Biosciences | 17 | 2024-05-22 | 2026-06-26 |
| First in Human Study of AZD9592 in Solid Tumors AZD9592, Osimertinib, 5-Fluorouracil (5-FU) - Advanced Solid Tumours, Carcinoma Non-small Cell Lung | Phase 1 | Active not recruiting | AstraZeneca | 190 | 2022-12-21 | 2026-09-25 |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies Rilvegostomig, Volrustomig, Sabestomig - Solid Tumor | Early Phase 1 | Active not recruiting | Presage Biosciences | 15 | 2021-07-26 | 2026-05-22 |
Head and Neck Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Lymphoma (1) · Melanoma (1) · Neoplasms (1) · Sarcoma (1)
Presage Biosciences (2) · AstraZeneca (1)
United States (3) · Australia (1) · Canada (1) · China (1) · France (1) · Italy (1) · Japan (1) · Malaysia (1) · South Korea (1) · Spain (1) · Taiwan (1)